Author

Justin L. Cope

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Genetic & Genomic Medicine· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:differential expression· 1 Approach:machine learning (classical)· 1 Approach:statistical model· 1 Research Focus:variant effect prediction· 1 Assay:whole-genome sequencing· 1

Frequent Co-Authors

Charles N. J. RavaraniiD· 2 shared Hannes A. BaukmanniD· 2 shared Marco Florian SchmidtiD· 2 shared Alexander R. E. C. Schwinges· 1 shared Colin BannardiD· 1 shared Erwin P. BöttingeriD· 1 shared Joern E. Klinger· 1 shared Jörn Klinger· 1 shared

Activity by Year

2021-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersGenetic & Genomic Medicine

Charles N. J. RavaraniORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Genetic & Genomic MedicineFrontiers in GeneticsPeer-reviewedOct 20, 2021

Interaction-based feature selection algorithm outperforms polygenic risk score in predicting Parkinson's Disease status

Jörn Klinger, Charles N. J. Ravarani, Hannes A. Baukmann…·Marco Florian Schmidt

The paper presents an interaction-based feature selection algorithm that outperforms polygenic risk scores in predicting Parkinson's Disease status using the PPMI dataset.

10 citations

humanwhole-genome sequencing

𝕏 PostBluesky

Genetic & Genomic MedicinemedRxivPreprintMay 18, 2021

Neutrophils cause critical illness in COVID-19 and reveal CDK6 inhibitors as potential treatment

Hannes A. Baukmann, Justin L. Cope, Charles N. J. Ravarani…·Marco Florian Schmidt

The paper identifies high neutrophil count as a causal trait in severe COVID-19 and suggests CDK6 inhibitors as potential treatment.

2 citations

humanbulk RNA-seq

𝕏 PostBluesky